21 Results for "

T24 bladder cancer cells

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "T24 bladder cancer cells" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-N2420
CAS No.: 3420-72-2
Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108719
CAS No.: 160337-95-1
Insulin glargine is a long-acting insulin analog. Insulin glargine has the effect of lowering blood sugar and can be used in the research of diabetes. In addition, high doses of Insulin glargine can promote the proliferation of bladder cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162318
CAS No.: 2946670-96-6
Research Areas:  

Cancer

MYC degrader 1 is a MYC degrader that recruits Cereblon (CRBN), with a Kd value of 145 nM and oral activity. MYC degrader 1 specifically binds MYC and GSPT1, recruits the CRBN E3 ubiquitin ligase complex, and induces MYC degradation via the ubiquitin-proteasome pathway. MYC degrader 1 downregulates KLHL42 expression, restores pRB1 protein levels, and re-establishes the sensitivity of MYC-overexpressing cancer cells to CDK4/6 inhibitors. MYC degrader 1 combined with Palbociclib (HY-50767) shows significant inhibition of tumor growth. MYC degrader 1 can be used in studies related to bladder cancer, prostate cancer, and breast cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-162318A
Target:  

c-Myc

Research Areas:  

Cancer

MYC degrader 1 TFA is a MYC degrader that recruits Cereblon (CRBN), with a Kd value of 145 nM and oral activity. MYC degrader 1 TFA specifically binds MYC and GSPT1, recruits the CRBN E3 ubiquitin ligase complex, and induces MYC degradation via the ubiquitin-proteasome pathway. MYC degrader 1 TFA downregulates KLHL42 expression, restores pRB1 protein levels, and re-establishes the sensitivity of MYC-overexpressing cancer cells to CDK4/6 inhibitors. MYC degrader 1 TFA combined with Palbociclib (HY-50767) shows significant inhibition of tumor growth. MYC degrader 1 TFA can be used in studies related to bladder cancer, prostate cancer, and breast cancer .
loading...
    loading...
Cat. No.: HY-P99899
CAS No.: 2052591-32-7
Synonyms: PR-1498487

Target:  

ADC Antibodies

Research Areas:  

Cancer

Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab can be used to synthesize antibody-drug conjugates (ADC). Samrotamab disrupts the LRRC15-SCG5 signaling module, binds to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, and binds to the lateral edge of the LRR solenoid while leaving the canonical concave β-sheet surface fully exposed. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration, and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research related to urothelial carcinoma, sarcoma, osteosarcoma, and undifferentiated pleomorphic sarcoma .
loading...
    loading...
Cat. No.: HY-171030
CAS No.: 2222067-12-9
Research Areas:  

Cancer

Pro-GA is a γ-glutamyl cyclotransferase (GGCT) inhibitor. Pro-GA inhibits the enzymatic activity of GGCT, disrupts glutathione homeostasis, induces the production of mitochondrial ROS, and upregulates the expression of p21, p27 and p16 in cells. Pro-GA inhibits the growth of cancer cells, induces cell cycle arrest and cellular senescence. Pro-GA exerts anti-tumor effects in breast cancer xenograft mouse models. Pro-GA can be used in research related to bladder cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-174086
CAS No.: 3071165-43-7
Research Areas:  

Cancer

PROTAC GPX4 degrader-4 is a potent GPX4 PROTAC degrader, with DC50 values of 1366.67 nM and 475.15 nM in T24 and RT4 cells, respectively. PROTAC GPX4 degrader-4 targets and degrades GPX4 protein via the ubiquitin-proteasome system, thereby inducing cellular ferroptosis. PROTAC GPX4 degrader-4 can be used for research on bladder cancer .
loading...
    loading...
Cat. No.: HY-W013852
CAS No.: 152460-10-1
Target:  

PKC

Research Areas:  

Cancer

PKC-IN-6 is a selective inhibitor of protein kinase C-α (PKC-α) with an IC50 of 240 μM. PKC-IN-6 shows no inhibitory activity against PKC-δ, PKA or EGF-R tyrosine kinase. PKC-IN-6 can be used in research related to bladder cancer .
loading...
    loading...
Cat. No.: HY-141649
CAS No.: 1648546-79-5
Research Areas:  

Cancer

Anticancer agent 251 (compound 7j) can induce cell death of bladder cancer cell T24 by inducing apoptosis, autophagy or ferroptosis .
loading...
    loading...
Cat. No.: HY-173280
CAS No.: 3035018-34-6
Synonyms: CHNQD-01228
Research Areas:  

Cancer

Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins. The IC50 value for the proliferation of T24 cells is 0.22 μM. It can also dose-dependently inhibit the migration and colony formation of T24 cells, induce G1 phase arrest and trigger Apoptosis. Brefeldin A 4-O-nicotinate exerts its anti-cancer activity by targeting the BMX protein to inhibit the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, as well as by inhibiting the Arf1 protein to eliminate bladder cancer stem cells and activate anti-tumor immunity. Brefeldin A 4-O-nicotinate can be used in the research related to bladder cancer .
loading...
    loading...
Cat. No.: HY-161341
Target:  

Photosensitizer

Research Areas:  

Cancer

β-Glucuronidase responsive conjugate 1 (compound 3) is a well-balanced photosensitizer which has photodynamic activity. β-Glucuronidase responsive conjugate 1 inhibits T-24 cell viability and growth with an IC50 of 0.2 μM. β-Glucuronidase responsive conjugate 1 can used to study bladder cancers .
loading...
    loading...
Cat. No.: HY-113636
CAS No.: 99624-28-9
Purity:  ≥97.0%
Kazinol A induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2 .
loading...
    loading...
Cat. No.: HY-173473
Research Areas:  

Cancer

Anticancer agent 272 (Compound 2) is an anticancer agent. Anticancer agent 272 has significant anti-bladder cancer cell (T-24) activity (IC50: 2.81 μM). Anticancer agent 272 consumes glutathione (GSH) through Fenton-like reaction, produces reactive oxygen species (ROS) and hydroxyl radicals (?OH), and induces apoptosis and ferroptosis. Anticancer agent 272 can enhance chemodynamic therapy (CDT) and promote tumor cell death through mitochondrial dysfunction and autophagy. Anticancer agent 272 has potential in the study of bladder cancer .
loading...
    loading...
Cat. No.: HY-N2420R
CAS No.: 3420-72-2
Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer .
loading...
    loading...
Cat. No.: HY-N15348
Aphidicolins B32 is a diterpenoid compound discovered in the marine fungus Botryotinia fuckeliana, exhibiting cytotoxic activity against human bladder cancer cells. It inhibits the proliferation of T24 cells in the G0/G1 phase, with an IC50 of 27.6 μM. Aphidicolins B32 holds potential for research in the field of cancer therapy .
loading...
    loading...
Cat. No.: HY-169406
Target:  

Glycosidase

Research Areas:  

Cancer

α-Glucosidase-IN-76 (Compound 4r) is an inhibitor for α-glucosidase with an IC50 of 5.44 μM. α-Glucosidase-IN-76 scavenges ABTS+ free radicals with a TEAC value of 0.49. α-Glucosidase-IN-76 inhibits the proliferation of T24 bladder cancer cell with IC50 of 1.74 μM .
loading...
    loading...
Cat. No.: HY-181489
CAS No.: 3023042-32-9
Target:  

SARS-CoV

Research Areas:  

Infection Cancer

SARS-CoV-2 3CLpro-IN-35 is a SARS-CoV-2 3CLpro inhibitor with an IC50 of 0.15 μM. SARS-CoV-2 3CLpro-IN-35 inhibits the proliferation of bladder cancer cells, exerts anti-SARS-CoV-2 activity, and exhibits low cytotoxicity in fibroblasts. SARS-CoV-2 3CLpro-IN-35 is applicable to research related to SARS-CoV-2 infection and bladder cancer .
loading...
    loading...
Cat. No.: HY-183312
Antitumor agent-217 is a dual mitochondria-targeted anticancer agent. Antitumor agent-217 exhibits potent and selective antiproliferative activity against bladder cancer cell line J82 (IC50 = 6.3 μM), and inhibits colony formation and migration of J82 cells. Antitumor agent-217 accumulates in mitochondria, alters mitochondrial morphology, reduces ATP production, increases ROS generation and decreases mitochondrial membrane potential. Antitumor agent-217 induces apoptosis (Apoptosis) and ferroptosis (Ferroptosis) in bladder cancer cells. Antitumor agent-217 can be used for the research of bladder cancer .
loading...
    loading...
Cat. No.: HY-187687
CAS No.: 2740603-37-4
Anticancer agent 359 is a ferroptosis inducer. Anticancer agent 359 inhibits the proliferation, colony formation and migration of bladder cancer cells in a concentration-dependent manner. Anticancer agent 359 induces ferroptosis by downregulating SREBP1 to inhibit FASN transcription, reducing the expression of NRF2/SLC7A11/GPX4, decreasing GSH, promoting ROS accumulation and lipid peroxidation; this effect is reversible by Ferrostatin-1 (HY-100579). Anticancer agent 359 acts synergistically with Talazoparib (HY-16106). Anticancer agent 359 inhibits tumor growth in vivo without obvious hepatotoxicity or nephrotoxicity. Anticancer agent 359 can be used in the research of bladder cancer .
loading...
    loading...
Cat. No.: HY-181353
Target:  

Glycosidase

Research Areas:  

Metabolic Disease Cancer

α-Glucosidase-IN-112 is an α-glucosidase inhibitor with an IC50 of 2.03 μM and a Ki of 0.44 μM. α-Glucosidase-IN-112 exerts antioxidant effects by scavenging ABTS + free radicals. α-Glucosidase-IN-112 exerts antiproliferative effects by inhibiting the proliferation of bladder cancer cells. α-Glucosidase-IN-112 can be used in research related to type 2 diabetes and bladder cancer .
loading...
    loading...